A
Andrew Johns Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
12 h-index
74 pubs
525 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Andrew Johns' research focuses on the clinical outcomes and toxicities associated with immune checkpoint inhibitors (ICIs) in cancer patients. His work has investigated the incidence, risk factors, and survival impacts of ICI-related adverse events, including thrombocytopenia and hepatitis. Johns has also examined prognostic markers, such as serum albumin, for predicting treatment response to ICIs and chemoimmunotherapy. His research includes studies on specific patient populations, such as older adults with advanced cancer, and explores the potential for SARS-CoV-2 mRNA vaccines to sensitize tumors to ICI therapy. Additionally, his work has involved comparing different methods for evaluating immunotherapy-related adverse events, such as manual chart review versus ICD claims data. Johns has an h-index of 12 with 74 total publications and 525 total citations.
Metrics
- h-index: 12
- Publications: 74
- Citations: 525
Selected Publications
-
Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation (2025)
Collaboration Network
Top Collaborators
Matthew T. Campbell
The University of Texas MD Anderson Cancer Center (US)
20 shared publications
- Toxicities From Antibody-Drug Conjugates
- Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
- Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
- CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
- Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma
Showing 5 of 20 shared publications
Madison Grogan
The Ohio State University (US)
17 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Showing 5 of 17 shared publications
Gregory A. Otterson
The Ohio State University (US)
17 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Showing 5 of 17 shared publications
Dwight H. Owen
The Ohio State University (US)
17 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Showing 5 of 17 shared publications
Carolyn J. Presley
The Ohio State University (US)
17 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Showing 5 of 17 shared publications
Amishi Y. Shah
The University of Texas MD Anderson Cancer Center (US)
15 shared publications
- Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
- Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
- CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
- Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma
- Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
Showing 5 of 15 shared publications
Lai Wei
The Ohio State University (US)
13 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Showing 5 of 13 shared publications
Mingjia Li
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
12 shared publications
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
Showing 5 of 12 shared publications
Kari Kendra
The Ohio State University (US)
12 shared publications
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
- Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
Showing 5 of 12 shared publications
Daniel Spakowicz
The Ohio State University (US)
10 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
- Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
Showing 5 of 10 shared publications
Sandip H. Patel
The Ohio State University (US)
10 shared publications
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
- Immune checkpoint inhibitor induced hepatitis: Risk factors, outcomes, and impact on survival.
- P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
Showing 5 of 10 shared publications
Erin M. Bertino
The Ohio State University (US)
10 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
- P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
Showing 5 of 10 shared publications
Nizar M. Tannir
Scripps MD Anderson Cancer Center (US)
10 shared publications
- Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
- Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
- CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
- Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma
- Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
Showing 5 of 10 shared publications
Marium Husain
The Ohio State University (US)
9 shared publications
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
- Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
- Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.
- Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy
Showing 5 of 9 shared publications
David P. Carbone
The Ohio State University (US)
9 shared publications
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
- Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
- P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics
Zainab Atiq
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Pharmacological Effects and Toxicity Studies
Vivek Yadala
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
COVID-19 Clinical Research Studies
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Pharmacological Effects and Toxicity Studies
Beatriz Cuevas
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
COVID-19 Clinical Research Studies
Mazin Safar
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Cancer Immunotherapy and Biomarkers
Syed Mujtaba Ali Naqvi
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Immune Response and Inflammation
COVID-19 Clinical Research Studies